Rapport Therapeutics (NASDAQ:RAPP) Trading Down 6.5% – Should You Sell?

Rapport Therapeutics (NASDAQ:RAPP)’s stock price was down 6.5% during trading on Friday . The stock traded as low as $20.56 and last traded at $20.56. Approximately 5,964 shares were traded during trading, a decline of 96% from the average daily volume of 157,690 shares. The stock had previously closed at $21.98.

Rapport Therapeutics Price Performance

The stock’s 50 day moving average is $22.57.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. FMR LLC boosted its position in Rapport Therapeutics by 10.1% during the third quarter. FMR LLC now owns 5,486,468 shares of the company’s stock worth $112,363,000 after acquiring an additional 503,117 shares during the last quarter. ARCH Venture Management LLC purchased a new position in shares of Rapport Therapeutics during the 2nd quarter worth $86,730,000. Johnson & Johnson acquired a new stake in shares of Rapport Therapeutics during the second quarter worth $58,105,000. Sofinnova Investments Inc. acquired a new stake in shares of Rapport Therapeutics during the second quarter worth $45,393,000. Finally, Perceptive Advisors LLC purchased a new stake in shares of Rapport Therapeutics in the second quarter valued at $17,403,000.

Rapport Therapeutics Company Profile

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.